HOME > TOP STORIES
TOP STORIES
-
BUSINESS Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
-
REGULATORY Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
-
BUSINESS Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
-
REGULATORY Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
-
REGULATORY Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
March 6, 2026
-
BUSINESS Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
-
REGULATORY Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
March 6, 2026
-
REGULATORY Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
-
BUSINESS Takeda Targets Psoriasis Market with Zasocitinib, Touts Edge in TYK2 Selectivity
March 4, 2026
-
BUSINESS Sumitomo Regains Growth Momentum, Eyes 350 Billion Yen from 2 Key Drugs in FY2028
March 3, 2026
-
BUSINESS Middle East Turmoil Raises Fears over API Shipments as Key Airports Shut
March 3, 2026
-
ORGANIZATION EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
-
BUSINESS Ono, AstraZeneca to End Japan Co-Promotion of Forxiga
March 2, 2026
-
BUSINESS Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
-
BUSINESS Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
-
COMMENTARY G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
-
BUSINESS Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
-
REGULATORY Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
-
BUSINESS Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
-
BUSINESS DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
